A Strategy to Minimize Reactive Metabolite Formation: Discovery of (S)-4-(1-Cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a Potent, Orally Bioavailable Corticotropin-Releasing Factor-1 Receptor Antagonist-Reference-Cited by-同舟云学术

A Strategy to Minimize Reactive Metabolite Formation: Discovery of (S)-4-(1-Cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a Potent, Orally Bioavailable Corticotropin-Releasing Factor-1 Receptor Antagonist

Published:2009-09-01 Issue:23 Volume:52 Page:7653-7668
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Hartz Richard A.¹,Ahuja Vijay T.¹,Zhuo Xiaoliang²,Mattson Ronald J.¹,Denhart Derek J.¹,Deskus Jeffrey A.¹,Vrudhula Vivekananda M.¹,Pan Senliang¹,Ditta Jonathan L.¹,Shu Yue-Zhong²,Grace James E.²,Lentz Kimberley A.²,Lelas Snjezana³,Li Yu-Wen³,Molski Thaddeus F.³,Krishnananthan Subramaniam⁴,Wong Henry⁴,Qian-Cutrone Jingfang²,Schartman Richard²,Denton Rex²,Lodge Nicholas J.³,Zaczek Robert³,Macor John E.¹,Bronson Joanne J.¹

Affiliation:

1. Neuroscience Discovery Chemistry

2. Pharmaceutical Candidate Optimization

3. Neuroscience Discovery Biology

4. Department of Chemical Synthesis

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm900716v

Reference51 articles.